It sounds like this InterMune situation is heating up.
Good sources tell me InterMune - a US-based bio-pharmaceutical company that specialises in making a drug to treat idiopathic pulmonary fibrosis - has begun working with bankers from Evercore alongside long-standing financial adviser Goldman Sachs to look at 'strategic options' for the business.
Showing posts with label Evercore Partners. Show all posts
Showing posts with label Evercore Partners. Show all posts
Monday, 11 August 2014
Subscribe to:
Posts (Atom)